Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bausch + lomb ireland - tetracaïnehydrochloride 10 mg/ml - eq. tetracaïne 8,79 mg/ml - oogdruppels, oplossing - 10 mg/ml - tetracaïnehydrochloride 10 mg/ml - tetracaine

USA - engelsk - NLM (National Library of Medicine)

akorn - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride 10 mg in 1 ml - tetracaine hydrochloride is indicated for the production of spinal anesthesia for procedures requiring two to three hours. spinal anesthesia with tetracaine hydrochloride is contraindicated in patients with known hypersensitivity to tetracaine hydrochloride or to drugs of a similar chemical configuration (ester-type local anesthetics), or aminobenzoic acid or its derivatives; and in patients for whom spinal anesthesia as a technique is contraindicated. the decision as to whether or not spinal anesthesia should be used for an individual patient should be made by the physician after weighing the advantages with the risks and possible complications. contraindications to spinal anesthesia as a technique can be found in standard reference texts, and usually include generalized septicemia, infection at the site of injection, certain diseases of the cerebrospinal system, uncontrolled hypotension, etc.

USA - engelsk - NLM (National Library of Medicine)

alcon laboratories, inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride 5 mg in 1 ml - tetracaine hydrochloride ophthalmic solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. none. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution 0.5% in pregnant women.  animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion.  the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution 0.5% and any potential adverse effects on the breastfed child from tetracaine hydrochloride ophthalmic solution 0.5% or from the underlying maternal condition. no human data on the effect of tetracaine hydrochloride ophthalmic solution 0.5% on fertility are available. safety in the pediatric population has been demonstrated in clinical trials.  efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. no overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

ΚΟΠΕΡ Α.Ε. ΑΡΙΣΤΟΒΟΥΛΟΥ 64, 11853 Κ. ΠΕΤΡΑΛΩΝΑ 3462102 3462108 - tetracaine hydrochloride - ey.dro.sol (ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 0,5% - tetracaine hydrochloride 5mg - tetracaine

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution, usp 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. tetracaine hydrochloride ophthalmic solution, usp 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, usp 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution, usp 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution, usp 0.5% and any potential adverse effects on the breastfed child from tetracaine hydroc

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bausch + lomb ireland - chlorhydrate de tétracaïne 10 mg/ml - eq. tétracaïne 8,79 mg/ml - collyre en solution - 10 mg/ml - chlorhydrate de tétracaïne 10 mg/ml - tetracaine

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bausch health ireland limited 3013 lake drive, citywest business campus d24 ppt3 dublin 24 (ierland) - tetracaine hydrochloride 10 mg/ml - oogdruppels, oplossing - water, gezuiverd ; zoutzuur (e 507), - tetracaine

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bausch health ireland limited 3013 lake drive, citywest business campus d24 ppt3 dublin 24 (ierland) - tetracaine hydrochloride 5 mg/ml - oogdruppels, oplossing - water, gezuiverd ; zoutzuur (e 507), - tetracaine

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires thea - tétracaïne (chlorhydrate de) 4 mg - collyre - 4 mg - pour un récipient unidose de 0,4 ml > tétracaïne (chlorhydrate de 4 mg - médicaments ophtalmologiques - classe pharmacothérapeutique - code atc : s01ha03tetracaine 1 pour cent thea, collyre en solution contient une substance active, la tétracaïne. cette substance est un anesthésique local capable de pénétrer dans certaines parties de l’œil comme la cornée et la conjonctive.ce médicament est indiqué comme anesthésique local au cours de différentes interventions chirurgicales ou différents examens de l’œil.

USA - engelsk - NLM (National Library of Medicine)

cameron pharmaceuticals - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride is indicated for the production of spinal anesthesia for procedures requiring two to three hours. spinal anesthesia with tetracaine hydrochloride is contraindicated in patients with known hypersensitivity to tetracaine hydrochloride or to drugs of a similar chemical configuration (ester-type local anesthetics), or aminobenzoic acid or its derivatives; and in patients for whom spinal anesthesia as a technique is contraindicated. the decision as to whether or not spinal anesthesia should be used for an individual patient should be made by the physician after weighing the advantages with the risks and possible complications. contraindications to spinal anesthesia as a technique can be found in standard reference texts, and usually include generalized septicemia, infection at the site of injection, certain diseases of the cerebrospinal system, uncontrolled hypotension, etc.